LLY

762.79

+0.4%↑

JNJ

174.31

-1.4%↓

ABBV

221.87

+0.84%↑

UNH

334.97

-1.8%↓

AZN

77.08

-0.7%↓

LLY

762.79

+0.4%↑

JNJ

174.31

-1.4%↓

ABBV

221.87

+0.84%↑

UNH

334.97

-1.8%↓

AZN

77.08

-0.7%↓

LLY

762.79

+0.4%↑

JNJ

174.31

-1.4%↓

ABBV

221.87

+0.84%↑

UNH

334.97

-1.8%↓

AZN

77.08

-0.7%↓

LLY

762.79

+0.4%↑

JNJ

174.31

-1.4%↓

ABBV

221.87

+0.84%↑

UNH

334.97

-1.8%↓

AZN

77.08

-0.7%↓

LLY

762.79

+0.4%↑

JNJ

174.31

-1.4%↓

ABBV

221.87

+0.84%↑

UNH

334.97

-1.8%↓

AZN

77.08

-0.7%↓

Home・Akciju saraksts・Axsome Therapeutics Inc

Axsome Therapeutics Inc

Slēgts

SektorsVeselības aprūpe

118.38 1.79

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

115.14

Max

118.57

Galvenie mērījumi
By Trading Economics
Ienākumi	11M -48M
Pārdošana	29M 150M
Peļņas marža	-31.973
Darbinieki	846
EBITDA	20M -37M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt (spēcīgs)
Prognoze 12 mēnešiem	+46.24% upside

Dividendes
By Dow Jones
Nākamie ieņēmumi	2025. g. 11. nov.

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	520M 5.8B
Iepriekšējā atvēršanas cena	116.59
Iepriekšējā slēgšanas cena	118.38

Ziņu noskaņojums

By Acuity

45%

55%

158 / 371 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Weak Bearish Evidence

107.24 / 112.29 Atbalsts un pretestība

Axsome Therapeutics Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 17. sept. 23:01 UTC

Iegādes, apvienošanās, pārņemšana

Santos Confirms XRG Consortium Pulls $18.7 Billion Takeover Bid -- Update

2025. g. 17. sept. 22:48 UTC

Iegādes, apvienošanās, pārņemšana

Santos Confirms XRG Consortium Pulls $18.7 Billion Takeover Bid

2025. g. 17. sept. 21:59 UTC

Peļņas

Cryptocurrency-Exchange Bullish Swings to Profit in First Report as Public Company

2025. g. 17. sept. 23:44 UTC

Tirgus saruna

Nikkei May Rise as Yen Weakens -- Market Talk

2025. g. 17. sept. 23:39 UTC

Tirgus saruna

Gold Rises Amid Prospects of Further Fed Rate Cuts -- Market Talk

2025. g. 17. sept. 22:20 UTC

Iegādes, apvienošanās, pārņemšana

Santos: XRG Consortium Wouldn't Agree to Appropriate Risk Allocation Between It and Santos Shareholders

2025. g. 17. sept. 22:20 UTC

Iegādes, apvienošanās, pārņemšana

Santos: XRG Consortium Wouldn't Agree to Acceptable Terms That Protected Value of Transaction

2025. g. 17. sept. 22:20 UTC

Iegādes, apvienošanās, pārņemšana

Santos Had Expressed Concern to XRG Consortium About Delays in Agreeing to Scheme Implementation Agreement

2025. g. 17. sept. 22:19 UTC

Iegādes, apvienošanās, pārņemšana

Santos: Consortium Notified Board of Decision to Withdraw Proposal on Weds Evening

2025. g. 17. sept. 22:18 UTC

Iegādes, apvienošanās, pārņemšana

Santos Confirms XRG Consortium Has Withdrawn Takeover Proposal

2025. g. 17. sept. 21:00 UTC

Peļņas

Darden Restaurants to Report Earnings. Why the Olive Garden Parent Is Expected to Stay Strong. -- Barrons.com

2025. g. 17. sept. 20:50 UTC

Tirgus saruna

Financial Services Roundup: Market Talk

2025. g. 17. sept. 20:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2025. g. 17. sept. 19:59 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2025. g. 17. sept. 19:59 UTC

Tirgus saruna

Treasury Yields, Dollar Rise as Fed Cuts, Powell Warns of Risks -- Market Talk

2025. g. 17. sept. 19:07 UTC

Tirgus saruna

Oil Futures Snap Three-Session Winning Streak -- Market Talk

2025. g. 17. sept. 18:43 UTC

Tirgus saruna

Treasury Yields, Dollar Reverse Course as Powell Talks to Reporters -- Market Talk

2025. g. 17. sept. 18:38 UTC

Tirgus saruna

U.S. Natural Gas Futures Mixed Ahead of Storage Data -- Market Talk

2025. g. 17. sept. 18:20 UTC

Tirgus saruna

Gold Dips After Quarter-Point Rate Cut -- Market Talk

2025. g. 17. sept. 18:18 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2025. g. 17. sept. 18:18 UTC

Tirgus saruna

Treasury Yields, Dollar Fall on Nearly Unanimous Fed Cut -- Market Talk

2025. g. 17. sept. 18:14 UTC

Tirgus saruna

Oil Slips Some More as Fed Makes Expected 25 Bp Rate Cut -- Market Talk

2025. g. 17. sept. 17:59 UTC

Tirgus saruna

Soyoil Takes Hit as Traders Consider EPA Proposal -- Market Talk

2025. g. 17. sept. 17:15 UTC

Iegādes, apvienošanās, pārņemšana

Netflix 'Has Won The Streaming Wars,' Analyst Says. The Stock Is a Buy. -- Barrons.com

2025. g. 17. sept. 17:06 UTC

Iegādes, apvienošanās, pārņemšana

Walmart Stock Heads for a Record High. The Retailer Could Become a Leader in 'Agentic' AI. -- Barrons.com

2025. g. 17. sept. 16:51 UTC

Peļņas

Correct: Exor 1H Net Loss -EUR624M

2025. g. 17. sept. 16:34 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2025. g. 17. sept. 16:34 UTC

Tirgus saruna

Bank of Canada Ditches Resilience Talk, Plays Up Slowing Growth -- Market Talk

2025. g. 17. sept. 16:25 UTC

Peļņas

Wolters Kluwer: July, August Saw a Slight Increase in Organic Growth Compared to 1H

2025. g. 17. sept. 16:23 UTC

Peļņas

Wolters Kluwer: Year-to-Date Performance In Line With 2025 Guidance

Salīdzinājums

Cenas izmaiņa

Axsome Therapeutics Inc Prognoze

Cenas mērķis

By TipRanks

46.24% augšup

Prognoze 12 mēnešiem

Vidējais 170.54 USD 46.24%

Augstākais 200 USD

Zemākais 144 USD

Pamatojoties uz 15 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Axsome Therapeutics Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

15 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 15 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Axsome Therapeutics Inc — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

107.24 / 112.29Atbalsts un pretestība

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

All events are bullish.

Noskaņojums

By Acuity

158 / 371 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Axsome Therapeutics Inc

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.